News
Back to Main News Page

TIAP Voices: Why Canadian Digital Health Companies Must Think Globally

By: Mobeen Lalani, TIAP Manager, Technology and Venture Development

Canadian digital health, artificial intelligence (AI), and medical device companies have long looked south to the United States for growth and validation—thanks to its vast healthcare market, access to capital, and proven track record in adopting innovation. However, increasing market concentration in a single geography can present significant challenges. Whether due to evolving trade dynamics, regulatory bottlenecks, or reimbursement pressures, the lesson is clear: to build resilient, globally competitive businesses, diversification must start earlier in a company’s lifecycle.

Thinking globally today is not about deprioritizing the U.S. market—it remains the world’s largest source of health innovation capital and partnerships. Instead, it’s about broadening opportunity and mitigating concentration risk. Companies that build optionality across multiple global markets are better positioned to adapt, attract sustained investment, and achieve scale.

The Shifting U.S. Market Environment

While the U.S. will remain a key commercialization destination for Canadian innovators, companies are encountering structural complexities—ranging from evolving regulatory expectations to varying procurement or supply chain demands. For early-stage companies, these dynamics can delay market entry or decrease margins. By contrast, companies that have prepared for multiple pathways to adoption—spanning Europe, the UK, the Middle East, and Asia-Pacific—can mitigate risks and sustain momentum even when one geography faces headwinds.

Why Thinking Beyond the U.S. Matters

  • Diversification Enhances Resilience: Companies reliant on a single market are more vulnerable to shifts in policy, reimbursement, or regulation. Geographic diversification helps maintain business continuity.
  • Global Demand is Accelerating: International health systems urgently need digital and AI-enabled solutions to strengthen access, efficiency, and workforce capacity.
  • Canadian Differentiation: Canada’s reputation for ethical AI, trusted data stewardship, and cross-cultural collaboration positions firms to win trust in new markets that are wary of U.S. influence. National AI institutes, including Amiiin Edmonton, Mila in Montreal, and the Vector Institute in Toronto, Canada, produce top talent, research, and discoveries which are trusted globally.

Tangible Ways Forward

  1. Start Early with International Regulatory Mapping: Building out an export roadmap should begin with comprehensive analyses of target market regulations (CE marking in Europe, TGA in Australia, HSA in Singapore, etc.) and reimbursement regimes. Partnering with local regulatory and/or reimbursement consultants can demystify regional compliance early, reduce costly pivots, and smooth product introduction.

Resources:

  • Global Affairs Canada’s Trade Commissioner Service (TCS) provides export advisory services, market assessments, and helps find local regulatory and reimbursement experts in over 160 cities worldwide.​
  • CanExport Innovation funding can cover costs like applying for certifications in international markets, seeking expert legal/regulatory advice, and translating/adapting materials for foreign regulators.​
  • Ontario’s life sciences strategy leverages Invest Ontario and a global network of trade and investment offices to promote Ontario health innovators and support entry into priority export markets.​
  • NRC IRAP advisory services help health tech SMEs refine product strategy, IP, and regulatory pathways as part of commercialization support for new technologies.​
  • Life Sciences Innovation Fund (LSIF) – Ontario provides up to about $500K to scale made-in-Ontario health solutions, including activities that strengthen commercialization and export readiness.​
  • Global Innovation Clusters (digital/health-related) can support collaborative R&D and validation work that builds evidence and standards alignment useful for multiple export markets.​
  1. Leverage International Consortia and Pilot Programs: Seek partnerships and pilot opportunities through organizations such as EIT Health (EU), NHS Innovation Hubs (UK), or APAC (Asia Pacific) Medtech networks. These collaborations not only open clinical validation channels but also allow Canadian startups to “test and iterate” solutions for region-specific needs while gaining reference customers. Provincial and federal partnerships and trade missions can accelerate relationship-building and business development activities.

Resources:

  1. Explore Cross-Border Digital Health Sandboxes: Tailor value propositions around local system needs, language, and workflow. Participate in regulatory sandboxes and public-private pilots from HealthTech hubs in Singapore, the Nordics, or Germany, where authorities offer real-world settings for foreign companies to test interoperability, privacy, and safety under regulator supervision.

Resources:

The Path Ahead

For Canadian digital health innovators, mastering international expansion is not just a defensive move—it’s a growth strategy. The U.S. will continue to be vital, but resilience lies in diversified pathways. By cultivating global partnerships, engaging in international pilots, and aligning early with multiple regulatory systems, Canadian companies can strengthen both their commercial outlook and their contribution to global health innovation.

Back To Top